<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03003546</url>
  </required_header>
  <id_info>
    <org_study_id>LS1681</org_study_id>
    <secondary_id>NCI-2016-01984</secondary_id>
    <secondary_id>LS1681</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT03003546</nct_id>
  </id_info>
  <brief_title>Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Phase I Trial of AR160 (Abraxane/Rituximab 160nm Nanoparticle) in Relapsed/Refractory B Cell Lymphomas Including Transformed Follicular Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the best dose and side effects of paclitaxel albumin-stabilized
      nanoparticle formulation (nab-paclitaxel)/rituximab-coated nanoparticle AR160 in treating
      patients with B-cell non-Hodgkin lymphoma that has come back or is not responding to
      treatment. Nab-paclitaxel/rituximab-coated nanoparticle AR160 is a combination of paclitaxel
      albumin-stabilized nanoparticle formulation and rituximab. Drugs used in chemotherapy, such
      as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the
      growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
      stopping them from spreading. Monoclonal antibodies, such as rituximab, may interfere with
      the ability of tumor cells to grow and spread. Giving paclitaxel albumin-stabilized
      nanoparticle formulation and rituximab may work better in treating patients with B-cell
      non-Hodgkin lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To establish the maximum tolerated dose (MTD) of nab-paclitaxel/rituximab-coated
      nanoparticle AR160 (AR160) in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
      (NHL). (Phase I)

      SECONDARY OBJECTIVES:

      I. To assess the toxicity and safety of AR160. II. To assess complete response rate (CR)
      progression free survival (PFS), and overall survival (OS) of AR160 with relapsed/refractory
      B-cell NHL.

      TERTIARY OBJECTIVES:

      I. Evaluate pharmacokinetics (PK) of AR160 in two formal PK studies, dose 1 of cycle 1 (48
      hours [h] PK analysis) and dose 1 of cycle 2 (24h PK analysis).

      OUTLINE: This is a dose-escalation study.

      Patients receive nab-paclitaxel/rituximab-coated nanoparticle AR160 intravenously (IV) over
      30-60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease
      progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 6 months for up to 5
      years.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD defined as the highest dose level patients develop a dose limiting toxicity assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>The maximum grade of each type of toxicity will be recorded for each patient. For each toxicity reported by dose level, the percentage of patients developing any degree of that toxicity as well as the percentage of patients developing a severe degree (grade 3 or higher) will be determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>A table will be constructed to display by dose level, the number of patients treated at that dose level, the number of cycle of treatment administered, DLT observed, progression-free survival time and overall survival time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>A table will be constructed to display by dose level, the number of patients treated at that dose level, the number of cycle of treatment administered, DLT observed, progression-free survival time and overall survival time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response assessed using The Lugano Classification Response criteria</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>A table will be constructed to display by dose level, the number of patients treated at that dose level, the number of cycle of treatment administered, DLT observed, progression-free survival time and overall survival time.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Aggressive Non-Hodgkin Lymphoma</condition>
  <condition>CD20 Positive</condition>
  <condition>Recurrent B-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Small Lymphocytic Lymphoma</condition>
  <condition>Refractory B-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Refractory Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (AR160)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive nab-paclitaxel/rituximab-coated nanoparticle AR160 IV over 30-60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (AR160)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel/Rituximab-coated Nanoparticle AR160</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (AR160)</arm_group_label>
    <other_name>AR160</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (AR160)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological confirmation of relapsed/refractory B-cell NHL, CD20+

               -  NOTE: patients with small lymphocytic lymphoma (SLL) are eligible however
                  patients with chronic lymphocytic leukemia (CLL) are not eligible

               -  Waldenstrom macroglobulinemia patients are not eligible; aggressive lymphoma
                  patients who are transplant eligible must have undergone a transplant

               -  The biopsy confirming relapse can be up to 24 weeks prior to registration as long
                  as there is no intervening therapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2

          -  Absolute neutrophil count (ANC) &gt;= 1500/mm^3

          -  Platelet count &gt;= 75,000/mm^3

          -  Hemoglobin &gt;= 8.0 g/dL

          -  Total bilirubin =&lt; 1.5 X upper limit of normal (ULN) or if total bilirubin is &gt; 1.5 X
             ULN, the direct bilirubin =&lt; ULN

          -  Alkaline phosphatase =&lt; 3 X ULN unless due to direct lymphoma involvement, and then =&lt;
             5 X ULN

          -  Aspartate transaminase (AST) =&lt; 3 X ULN unless due to direct lymphoma involvement, and
             then =&lt; 5 X ULN

          -  Calculated creatinine clearance must be &gt;= 30 ml/min using the Cockcroft-Gault formula

          -  Life expectancy &gt;= 3 months

          -  Ability to provide written informed consent

          -  Willing to return to enrolling institution for follow-up (during the treatment and
             observation phases of the study)

          -  Willing to provide tissue for central review blood samples for correlative research
             purposes

          -  No other therapy with demonstrated clinical benefit in relapsed/refractory B-cell NHL
             available to the patient

          -  Negative pregnancy test done =&lt; 7 days prior to registration, for women of
             childbearing potential only

        Exclusion Criteria:

          -  Any of the following:

               -  Pregnant women

               -  Nursing women

               -  Men or women of childbearing potential who are unwilling to employ adequate
                  contraception

          -  Active central nervous system (CNS) lymphoma or cerebrospinal fluid involvement with
             malignant lymphoma cells that requires therapy

          -  Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment
             of the investigator, would make the patient inappropriate for entry into this study or
             interfere significantly with the proper assessment of safety and toxicity of the
             prescribed regimens

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Patients who received most recent therapy =&lt; 4 weeks prior to registration; NOTE: use
             of systemic steroid therapy is allowed pretreatment

          -  Receiving any other investigational agent which would be considered as a treatment for
             the primary neoplasm

          -  Patients must be disease-free of prior invasive malignancies for &gt; 5 years prior to
             registration with the exception of curatively-treated basal cell or squamous cell
             carcinoma of the skin or carcinoma in situ of the cervix

          -  Patients with &gt;= 25% of the bone marrow radiated for other diseases

          -  Other medical conditions including but not limited to:

               -  History of liver disease such as cirrhosis, chronic active hepatitis, chronic
                  persistent hepatitis or hepatitis B or C

               -  Active infection requiring parenteral antibiotics

               -  New York Heart Association class II-IV congestive heart failure (serious cardiac
                  arrhythmia requiring medication)

               -  Myocardial infarction or unstable angina =&lt; 6 months prior to registration

               -  Congestive heart failure requiring use of ongoing maintenance therapy for
                  life-threatening ventricular arrhythmias

               -  Clinically significant peripheral vascular disease

               -  History of CNS disease (e.g., primary brain tumor, vascular abnormalities, etc.),
                  clinically significant stroke or transient ischemic attack (TIA) =&lt; 6 months
                  prior to registration, seizures not controlled with standard medical therapy

               -  Neuropathy Ëƒ grade 3

          -  Administration of strong CYP2C8 or CYP3A4 inhibitors or inducers =&lt; 10 days prior to
             registration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Habermann</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Thomas M. Habermann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2016</study_first_submitted>
  <study_first_submitted_qc>December 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2016</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

